Allarity Therapeutics, Inc. (ALLR) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Allarity Therapeutics, Inc.
Address
210 Broadway
Boston, MA 02139
United States of America (the)
Phone
401 426 4664
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
December 21, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Thomas H. Jensen | Founder, Chief Executive Officer & Director | 1.06M | 1978 |
| Steen Meier Knudsen | Founder & Chief Scientific Officer | 236,802 | 1961 |
| Jeffrey S. Ervin | Chief Financial Officer | 278,148 | 1978 |
| Jeremy R. Graff | President & Chief Development Officer | 762,933 | 1970 |
| Jose L. Iglesias | Consultant Chief Medical Officer | 0 | 1957 |
Description
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
